DrugPatentWatch Database Preview

Apgdi Company Profile

APGDI has one approved drug.

There are seven US patents protecting APGDI drugs.

There are one hundred and nine patent family members on APGDI drugs in twenty-nine countries and nineteen supplementary protection certificates in fourteen countries.

Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apgdi	MYRBETRIQ	mirabegron	TABLET, EXTENDED RELEASE;ORAL	202611-001	Jun 28, 2012		RX	Yes	Yes		➤ Sign Up				➤ Sign Up
Apgdi	MYRBETRIQ	mirabegron	TABLET, EXTENDED RELEASE;ORAL	202611-001	Jun 28, 2012		RX	Yes	Yes	7,342,117	➤ Sign Up		Y		➤ Sign Up
Apgdi	MYRBETRIQ	mirabegron	TABLET, EXTENDED RELEASE;ORAL	202611-002	Jun 28, 2012		RX	Yes	Yes	8,772,315	➤ Sign Up				➤ Sign Up
Apgdi	MYRBETRIQ	mirabegron	TABLET, EXTENDED RELEASE;ORAL	202611-002	Jun 28, 2012		RX	Yes	Yes	7,982,049	➤ Sign Up	Y			➤ Sign Up
Apgdi	MYRBETRIQ	mirabegron	TABLET, EXTENDED RELEASE;ORAL	202611-001	Jun 28, 2012		RX	Yes	Yes	6,346,532	➤ Sign Up	Y	Y		➤ Sign Up
Apgdi	MYRBETRIQ	mirabegron	TABLET, EXTENDED RELEASE;ORAL	202611-002	Jun 28, 2012		RX	Yes	Yes	6,562,375	➤ Sign Up	Y			➤ Sign Up
Apgdi	MYRBETRIQ	mirabegron	TABLET, EXTENDED RELEASE;ORAL	202611-002	Jun 28, 2012		RX	Yes	Yes	8,835,474	➤ Sign Up				➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Apgdi	MYRBETRIQ	mirabegron	TABLET, EXTENDED RELEASE;ORAL	202611-001	Jun 28, 2012	6,699,503	➤ Sign Up
Apgdi	MYRBETRIQ	mirabegron	TABLET, EXTENDED RELEASE;ORAL	202611-002	Jun 28, 2012	6,699,503	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Extended-release Tablets	25 mg and 50 mg	➤ Subscribe	2016-06-28

Subscribe to access the full database, or try a Free Trial
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2004041276	➤ Sign Up
Indonesia	23989	➤ Sign Up
Austria	500827	➤ Sign Up
Hungary	229295	➤ Sign Up
Canada	2704298	➤ Sign Up
Norway	20052691	➤ Sign Up
Canada	2305802	➤ Sign Up
Country	Patent Number	Estimated Expiration

Subscribe to access the full database, or try a Free Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1559427	168 5014-2013	Slovakia	➤ Sign Up	PRODUCT NAME: MIRABEGRON; REGISTRATION NO/DATE: EU/1/12/809/001 - EU/1/12/809/014 20121220
1559427	C20130015 00094	Estonia	➤ Sign Up	PRODUCT NAME: MIRABEGROON;REG NO/DATE: K(2012)9945 (LOPLIK) 20.12.2012
1028111	CA 2013 00029	Denmark	➤ Sign Up	PRODUCT NAME: MIRABEGRON OR SALTS THEREOF; REG. NO/DATE: EU/1/12/809/001-014 20121220
1559427	457	Finland	➤ Sign Up
1559427	122013000047	Germany	➤ Sign Up	PRODUCT NAME: MIRABEGRON ODER EIN SALZ DAVON; NAT. REGISTRATION NO/DATE: EU /1/12/809/001-014 20121220; FIRST REGISTRATION: EU EU/1/12/809/001-014 20121220
1559427	CR 2013 00028	Denmark	➤ Sign Up	PRODUCT NAME: MIRABEGRON OR A SALT THEREOF; REG. NO/DATE: EU/1/12/809/001-014 20121220
1559427	300599	Netherlands	➤ Sign Up	PRODUCT NAME: MIRABEGRON EN ZOUTEN ERVAN; REGISTRATION NO/DATE: EU/1/12/809/001-014 20130107
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.